Heinzelmann-Schwarz Viola A, Gardiner-Garden Margaret, Henshall Susan M, Scurry James, Scolyer Richard A, Davies Michael J, Heinzelmann Matthias, Kalish Larry H, Bali Anish, Kench James G, Edwards Lyndal S, Vanden Bergh Patricia M, Hacker Neville F, Sutherland Robert L, O'Brien Philippa M
Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, Australia.
Clin Cancer Res. 2004 Jul 1;10(13):4427-36. doi: 10.1158/1078-0432.CCR-04-0073.
A better understanding of the molecular pathways underlying the development of epithelial ovarian cancer (EOC) is critical to identify ovarian tumor markers for use in diagnostic or therapeutic applications. The aims of this study were to integrate the results from 14 transcript profiling studies of EOC to identify novel biomarkers and to examine their expression in early and late stages of the disease.
A database incorporating genes identified as being highly up-regulated in each study was constructed. Candidate tumor markers were selected from genes that overlapped between studies and by evidence of surface membrane or secreted expression. The expression patterns of three integral membrane proteins, discoidin domain receptor 1 (DDR1), claudin 3 (CLDN3), and epithelial cell adhesion molecule, all of which are involved in cell adhesion, were evaluated in a cohort of 158 primary EOC using immunohistochemistry.
We confirmed that these genes are highly overexpressed in all histological subtypes of EOC compared with normal ovarian surface epithelium, identifying DDR1 and CLDN3 as new biomarkers of EOC. Furthermore, we determined that these genes are also expressed in ovarian epithelial inclusion cysts, a site of metaplastic changes within the normal ovary, in borderline tumors and in low-grade and stage cancer. A trend toward an association between low CLDN3 expression and poor patient outcome was also observed.
These results suggest that up-regulation of DDR1, CLDN3, and epithelial cell adhesion molecule are early events in the development of EOC and have potential application in the early detection of disease.
更好地理解上皮性卵巢癌(EOC)发生发展的分子途径对于识别用于诊断或治疗的卵巢肿瘤标志物至关重要。本研究的目的是整合14项EOC转录谱研究的结果,以识别新的生物标志物,并检测它们在疾病早期和晚期的表达情况。
构建了一个数据库,该数据库纳入了在每项研究中被确定为高度上调的基因。候选肿瘤标志物从各研究之间重叠的基因中选取,并依据表面膜或分泌表达的证据来确定。使用免疫组织化学方法,在158例原发性EOC队列中评估了三种整合膜蛋白(盘状结构域受体1(DDR1)、紧密连接蛋白3(CLDN3)和上皮细胞粘附分子,它们均参与细胞粘附)的表达模式。
我们证实,与正常卵巢表面上皮相比,这些基因在EOC的所有组织学亚型中均高度过表达,确定DDR1和CLDN3为EOC的新生物标志物。此外,我们还确定这些基因在卵巢上皮包涵囊肿(正常卵巢内化生改变的部位)、交界性肿瘤以及低级别和低分期癌症中也有表达。还观察到CLDN3低表达与患者预后不良之间存在关联趋势。
这些结果表明,DDR1、CLDN3和上皮细胞粘附分子的上调是EOC发生发展的早期事件,在疾病的早期检测中具有潜在应用价值。